AKRO: Akero Therapeutics Inc Company Value to Net Income

Symbol and logo of brand Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics relies on a transparent scientific approach to MASH therapy, which is supported by the P/E multiple level. The -15.10 mark captures this indicator, signaling a balance between safety and yield. However, fierce competition in the metabolic drug market creates high risks, while environmental policy remains strictly formal.

P/E Multiple: Akero Therapeutics Inc (AKRO) for 07/04/2022 - 12/20/2025

Comprehensive metric breakdowns and analytics for Akero Corp (AKRO)

- price and consensus price forecast:
Summary company analysis:Akero Therapeutics, Inc.
Finished products of Akero Therapeutics Inc

For the biotech sector, where Akero Therapeutics (AKRO) is developing a portfolio of drugs for metabolic disorders, this ratio serves as a tool for assessing market expectations regarding future earnings. The relationship between the current quote and net income, reflected in the price-to-earnings (P/E) ratio dynamics, allows for a comparison of the share price with the fundamental stability of the business, which is supported by the diversification of clinical trials.